Monsenso participates in new project to investigate what works best for patients with depression after discharge from psychiatric treatment

Monsenso participates in new project to investigate what works best for patients with depression after discharge from psychiatric treatment

by | Feb 28, 2023 | mHealth, News

Depression is more common than one might think. In Denmark, it is estimated that between 7-12% of men and 15-25% of women suffer from depression at least once in their lifetime [1], which means that approximately 150.000 Danes live with moderate to severe depression at any given time [2]. But how do patients who have received psychiatric treatment for depression experience the sector-transition into the primary sector? And what are their needs for treatment and care from different healthcare sectors? The DEPRIC research project is now trying to find answers and thereby develop a new treatment model for depression across healthcare sectors in Denmark.

The transitional phase from inpatient wards into the primary sector can represent a vulnerable period for patients suffering from depression [3,4], with “high risks of relapse and readmission” [5] . The research project DEPRIC thus aims to establish a new treatment model for depression across the healthcare sectors in Denmark. The project is led by PhD student Anne Sofie Mosborg Aggestrup from the Mental Health Services in the Capital Region of Denmark. The DEPRIC project began in October 2021, and the project now offers patients who have completed a treatment course for severe depression at an affective disorders outpatient unit at the Mental Health Centre Copenhagen to participate in this cross-sectoral study by self-reporting data in an application (app) [6].

Throughout the research project so far, interviews, focus groups, and a group interview have been conducted with participating patients, healthcare professionals, and job consultants across sectors. In addition, the project will conduct workshops during the autumn of 2023. Currently, patients will be provided with the Monsenso digital health solution, an app that will allow them to register relevant data throughout the research project. This self-reported patient data will entail, for instance, data on the patients’ mood, sleep patterns, mental well-being, use of medication, connections to the labour market, and on why and how often they have approached specialist groups after their treatment course in the psychiatry [6]. 

It is anticipated that patients will begin their app registrations at the end of February 2023, and will then register every second week for a period of six months. The researchers behind the DEPRIC project aim to establish a more coherent patient course by involving patients, healthcare professionals, and job consultants in developing a new treatment model across healthcare sectors in Denmark. The researchers hypothesize that this will promote patients’ recovery process from depression, and reduce relapses of depression and psychiatric hospitalizations after the patients’ discharge from outpatient psychiatric treatment.

“Our aim is to help provide better health with better data. We are looking forward to contributing to this project and helping patients with mental illness transition across sectors more seamlessly for a better patient experience and higher quality of life”, says Thomas Lethenborg, CEO at Monsenso.

 “The self-registrations in the app will help us to identify factors and parameters to support patients on their pathway into the primary healthcare sector. Together with interviews, focus groups, group interviews, and workshops, the data in the app will help to develop a new treatment model that aims to prevent relapse of depression”, says Anne Sofie Mosborg Aggestrup, PhD student at the University of Copenhagen.
——————————————————————————————————————————-
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

References:
[1] Kessing, L.V. (2021). Depression, forekomst. Sundhed.dk.
https://www.sundhed.dk/borger/patienthaandbogen/psyke/sygdomme/depression/depression-forekomst/#:~:text=Depression%20er%20hyppig.,de%20lettere%20og%20moderate%20depressioner.

[2] Videbech, P., & Deleuran, A. (). The Danish Depression Database. Clinical Epidemiology, 8, 475–478.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098510/

[3] Dunker Svendsen, S., Aggestrup, A.S., Nørregaard, L.B., Løventoft, P., Præstegaard, A., Danilenko, K.V., Frost, M., Knorr, U., Hageman, I., Vedel Kessing, L. & Martiny, K. (2019). Circadian reinforcement therapy in combination with electronic self-monitoring to facilitate a safe post-discharge period of patients with depression by stabilizing sleep: protocol of a randomized controlled trial. BMC Psychiatry, 19, 124. https://doi.org/10.1186/s12888-019-2101-z

[4] Tønning, M.L., Faurholt-Jepsen, M., Frost, M., Martiny, K., Tuxen, N., Rosenberg, N., Busk, J., Winther, O., Melbye, S.A., Thaysen-Petersen, D., Aamund, K.A., Tolderlund, L., Bardram, J.E. & Kessing, L.V. (2021). The effect of smartphone-based monitoring and treatment on the rate and duration of psychiatric readmission in patients with unipolar depressive disorder: The RADMIS randomized controlled trial. Journal of Affective Disorders, 282, 354-363. https://pubmed.ncbi.nlm.nih.gov/33421863/

[5] Lauritsen, L., Andersen, L., Olsson, E., Søndergaard, S.R., Nørregaard, L.B., Løventoft, P.K., Svendsen, S.D., Frøkjær, E., Jensen, H.M., Hageman, I., Kessing, L.V. & Martiny, K. (2017). Usability, Acceptability, and Adherence to an Electronic Self-Monitoring System in Patients With Major Depression Discharged From Inpatient Wards. Journal of Medical Internet Research,19(4), e123. https://pubmed.ncbi.nlm.nih.gov/28432040/

[6] Madsen, M.B. (2023). Forskere vil forbedre overgange i behandling til mennesker med depression gennem en brugerinddragende indsats. Region Hovestandens Psykiatri.
https://www.psykiatri-regionh.dk/presse-og-nyt/Nyheder-og-pressemeddelelser/Sider/forskningsprojektet-depric.aspx

BOOK A DEMO
European community-based intervention project will use Monsenso’s platform to prevent mental illness

European community-based intervention project will use Monsenso’s platform to prevent mental illness

by | Dec 15, 2022 | mHealth, News

Together with a European consortium of partners, Monsenso has received a grant letter on a new community-based intervention project that includes development and trial of a digital health intervention delivered on Monsenso’s platform to prevent mental illness among vulnerable groups.

Global trends such as war, economic crisis, climate changes, migration, pandemics and ageing population place increasing stress and pressure on European societies. To be able to adapt to fast-changing situations, scalable intervention programmes targeted at building resilience and enhancing self-help competency to prevent mental illness are needed.

Upon receiving this grant letter, Monsenso is now entering into grant agreement negotiations with a consortium of leading researchers in clinical psychology, internet-based therapy, AI and community mental health providers across Europe. The aim of the project is to develop and trial an AI-enabled personalised self-care program based on Monsenso’s platform to help prevent mental illness for high-risk groups. The five-year project is anticipated to start in Q2-2023 and is expected to contribute with DKK 5.7 mio to Monsenso.

“This is the second AI-enabled personalised therapy project that we plan to start in the coming year, and it comes after finalising another European research project this year, where results showed significant effect of delivering digital cognitive behavioral therapy for prevention of mental illness. We will build on the evidence and experience of previous projects and further develop our platform to provide personalised, AI-driven digital programs for people at risk of developing mental illness, so that they can get easy and timely access to evidence-based support”, says Thomas Lethenborg, CEO of Monsenso.

Further information on the project including consortium members, funding program and population groups targeted will be communicated upon signature of a grant agreement, which is expected in Q1 of 2023.
——————————————————————————————————————————-
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

BOOK A DEMO
Monsenso to participate in AI-enabled personalised mental health therapy project

Monsenso to participate in AI-enabled personalised mental health therapy project

by | Dec 13, 2022 | mHealth, News

Monsenso and a consortium of partners have received a grant letter from a funding entity to develop and trial a new, AI-enabled personalised therapy concept for people with mental disorders.

Currently, digital mental health interventions are largely developed as a one-size-fits-all approach, where patients get a fixed 6-12 week intervention and where drop-out rates are relatively high.

With the grant letter received, Monsenso is entering grant agreement negotiations with a consortium of leading researchers in clinical psychology, internet-based therapy, health economics and AI to develop and trial a new AI-enabled personalised care concept based on Monsenso’s platform. The four-year project is anticipated to start in Q2-2023 and is expected to contribute with DKK 3.9 mio to Monsenso.

“With this project, we will further develop our platform’s ability to deliver personalised digital treatment programs and to ensure optimal adherence to treatment. By leveraging patients’ own data and artificial intelligence, the aim is to be able to give more engaging and personalised care based on patients’ actual state, so that patients are offered the right treatment at the right time in a scalable way”, says Thomas Lethenborg, CEO of Monsenso.

Full disclosure of the project details including consortium members, funding program, and disorder area will be possible upon signature of the grant agreement, which is expected in Q1 of 2023.
——————————————————————————————————————————-
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

BOOK A DEMO
Monsenso releases enhanced version of its clinical web portal & refreshed patient app

Monsenso releases enhanced version of its clinical web portal & refreshed patient app

by | Dec 1, 2022 | mHealth, News

Monsenso releases an enhanced version of its clinical web portal and a refreshed patient app. The product enhancements entail an improved and even more intuitive user interface of the solution’s patient app and clinical web portal in order to enhance remote patient monitoring and treatment support for clinicians, as well as the communication and collaboration between clinician and patient.

Among others, the enhancements allow clinicians to recommend treatment content to the patients individually to support personalised treatment. Clinicians can now recommend their patients to do specific exercises, visit the library with psychoeducational content or answer a specific clinical questionnaire. Once the clinician has made a recommendation via the clinical web portal, patients are notified and it is immediately emphasised in the patient’s app. This allows clinicians to provide more personalised treatment and also helps engage and empower patients in taking care of their own mental health.

The product enhancements result from an extensive, user-centered design process involving patients and clinicians in both design and testing phases to ensure the enhancements meet the needs of our users.

“We are excited to offer an improved version of our digital health solution to partners, clients, and patients. The feedback we have received during extensive internal and external testing periods has been excellent, and we are looking forward to empowering individuals, their carers, and clinicians even more on the treatment pathway”, says CEO, Thomas Lethenborg.
——————————————————————————————————————————-
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

BOOK A DEMO
Monsenso signs contract with private Danish psychiatric clinic Appia Klinikken in Søborg

Monsenso signs contract with private Danish psychiatric clinic Appia Klinikken in Søborg

by | Dec 1, 2022 | Mental Illness, mHealth, News

Monsenso signs a contract with the private Danish psychiatric clinic Appia Klinikken in Søborg, Zealand. The Monsenso digital health solution will be implemented at the beginning of 2023 and will be used to support patients and clinicians at the clinic.

Appia Klinikken is a Danish specialist psychiatric clinic offering treatment and support to individuals suffering from mental illness. Though the clinic has a focus on child and adolescent mental health, it offers treatment to individuals of all age groups.

The team of psychologists and psychiatrists at Appia Klinikken is led by specialist psychiatrist Mie Bonde, who “is professionally recognized for her holistic approach and for her work with clients with ADHD and/or ASD diagnoses, as well as clients with abuse combined with diagnosis(es)” [1].

The Monsenso solution will be used at Appia Klinikken for two different purposes. Primarily, the Monsenso solution will be used to screen patients while they are waiting for treatment and to monitor them during treatment. Secondly, the Monsenso solution will be used to collect data for effect documentation of a newly established type of treatment called “hypnotherapy” and for use of medication.

Specialist psychiatrist Mie Bonde says: “The Monsenso digital health solution will not only enable us to support patients more actively during treatment, but also to give patients information on how to reduce stress while they are still waiting to receive treatment. Waiting lists are something we cannot avoid entirely, but tools like the Monsenso solution enable us to make them more proactive”.
——————————————————————————————————————————-
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

References:
[1] Appia Klinikken (n.d.). Appia Klinikken – Vejenes dronning.
https://www.appia-klinikken.dk/

BOOK A DEMO
The Momentum Trial: How digital tools can support patient-centered care & shared decision-making

The Momentum Trial: How digital tools can support patient-centered care & shared decision-making

by | Nov 10, 2022 | Mental Illness, News, SCHIZOPHRENIA

In the delivery of mental health services, shared decision-making (SDM) is increasingly becoming more important [1]. SDM can be defined as a collaborative process between patient and health care provider, enabling joint treatment decisions and patient-centered care [2]. Research suggests that in mental healthcare, SDM could “contribute to recovery-oriented care by inviting the patient to have more control and be more involved in their treatment decisions” [2]. 

However, many mental health care providers are still reluctant to incorporate SDM into their treatment offers, as they believe it to be unfit for individuals suffering from severe mental illness, as well as to be time-consuming and thus a burden [3,4]. To overcome these challenges of incorporating SDM into daily practices, healthcare professionals have been encouraged to utilize “tools to support the SDM process” [2]. 

Increased focus has thus been placed on how digital interventions could support SDM in mental healthcare [2]. The Momentum Trial is a study investigating how using a smartphone app as a support tool could help “individuals suffering from schizophrenia-spectrum disorders in an outpatient treatment setting” [5]. 

During the trial, 194 participants were randomized either to receive “specialized early intervention treatment with the Momentum app” (intervention group) or to receive regular treatment without a smartphone app (control group) [5]. The Monsenso digital health solution, consisting of a patient app and a clinical web portal, was used for the intervention group. The Monsenso solution provided tools such as psychoeducational material, daily self-assessments, and action plans in the patient app, as well as patient insights in the clinical web portal [2].

As a primary outcome, it was investigated whether the individuals from the two groups would show a difference in self-perceived patient activation. Patient activation can play an important role in successful SDM processes, as patients who are more active and engaged in their treatment “feel confident when collaborating with their provider, and have the knowledge and skills to manage their condition” [2]. 

As secondary outcomes, it was investigated whether the individuals from the two different groups would show a difference in the self-perceived feeling of hope and optimism, self-efficacy, confidence in communicating with their provider, therapeutic alliance between the patient and provider, feeling prepared to make a treatment decision, and satisfaction with treatment [2]. 

Results were evaluated at baseline, as well as 3 and 6 months post-baseline. Promisingly, the Momentum Trial showed a significant effect of a digital SDM tool on the subjective level of patient activation, confidence in communicating with one’s provider, and feeling prepared for decision-making at the postintervention time point [2]. 

Though no statistically significant effects could be found related to the digital SDM intervention’s effect on working alliance, treatment satisfaction, clinical outcomes, and hope, the results from the Momentum Trial “confirm [the] hypothesis that a digital SDM tool may promote patient activation by supporting the collaborative process between patients and their providers” [2]

Monsenso CEO Thomas Lethenborg says: “The Momentum Trial shows how promising digital tools are in supporting shared decision-making. At Monsenso, we are proud to have been involved in this research project, and look forward to empowering individuals and clinicians even more on the treatment pathway”.
——————————————————————————————————————————-

About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com

References:
[1] Alguera-Lara, V., Dowsey, M., Ride, J., Kinder, S. & Castle, D. (2017). Shared decision making in mental health: the importance for current clinical practice. Australas Psychiatry, 25(6), 578-582. 

[2] Vitger, T., Hjorthøj, C., Austin, S.F., Petersen, L., Tønder, E.S., Nordentoft, M. & Korsbek, L. (2022). A Smartphone App to Promote Patient Activation and Support Shared Decision-making in People With a Diagnosis of Schizophrenia in Outpatient Treatment Settings (Momentum Trial): Randomized Controlled Assessor-Blinded Trial. Journal of Medical Internet Research, 24(10), e40292.
https://www.jmir.org/2022/10/e40292

[3] Hamann, J. & Heres, S. (2014). Adapting shared decision making for individuals with severe mental illness. Psychiatric Services, 65(12), 1483-1486.
https://ps.psychiatryonline.org/doi/full/10.1176/appi.ps.201400307

[4] Waldemar, A.K., Esbensen, B.A., Korsbek, L., Petersen, L. & Arnfred, S (2019). Recovery-oriented practice: participant observations of the interactions between patients and health professionals in mental health inpatient settings. International Journal of Mental Health Nursing, 28(1), 318-329. https://onlinelibrary.wiley.com/doi/10.1111/inm.12537

[5] Korsbek, L. (n.d.). The Momentum Trial: The efficacy of using a smartphone application to support shared decision making for people with a diagnosis of schizophrenia in an outpatient treatment setting. Open Patient data Explorative Network.
https://open.rsyd.dk/OpenProjects/openProject.jsp?openNo=451&lang=da

​​

BOOK A DEMO